Genital warts are one of the most common sexually transmitted conditions worldwide, with somewhere between 160 and 289 new cases per 100,000 people diagnosed each year in countries that track them closely. The rates vary sharply by age, sex, and geography, and they have shifted over the past two decades thanks to HPV vaccination programs. But the headline numbers only tell part of the story, because who gets counted depends heavily on how and where researchers look.
Overall Rates and Why the Range Is So Wide
If you look across systematic reviews of genital wart data from multiple countries, the numbers spread out more than you might expect. One large review covering studies from Australia, Europe, and North America found that the overall annual incidence of genital warts ranged from 160 to 289 per 100,000 people, with a median around 195 per 100,000. Prevalence based on medical records or insurance claims ranged from about 0.13% to 0.56%, but when researchers actually examined people’s genitals in clinical settings, prevalence jumped to between 0.2% and 5.1%.1PubMed Central. Systematic review of the incidence and prevalence of genital warts A more recent global review found an even wider spread, with prevalence ranging from 0.5% to 33.1% and incidence from 24 to 2,940 per 100,000 person-years across mixed-sex populations.2PubMed. Epidemiologic, clinical, and economic burden of anogenital warts among adults: A global systematic review
That enormous range reflects real differences in study design. When you rely on insurance billing codes or clinic charts, you only catch people who sought care and whose provider submitted the right code. Many people with genital warts never visit a doctor for them, either because the warts are small and unnoticed, because they resolve on their own, or because of embarrassment. Genital examination studies catch more cases but are harder and more expensive to run, so they tend to be smaller and more localized. In the United States alone, estimates suggest between 500,000 and one million new cases are diagnosed each year, and even that figure probably undercounts the true burden.3PubMed Central. Genital warts: a comprehensive review
Geography matters too. Most of the well-collected epidemiological data comes from high-income countries with robust surveillance systems and insurance databases. Many low- and middle-income countries have far less comprehensive data, which means global estimates are tilted toward what happens in wealthier nations.
Peak Ages for Women and Men
Genital warts are overwhelmingly a disease of young adults, but the peak age differs by sex. Among women, incidence is highest in those aged 20 to 24, at roughly 6.3 per 1,000 person-years in a large U.S. study conducted before HPV vaccine recommendations went into effect. Among men, the same age group had the highest rate too, but at about 2.9 per 1,000 person-years.4PubMed. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations Insurance claims data tell a broadly similar story, with the highest costs among women aged 20 to 24 (about 6.2 cases per 1,000 person-years) and among men aged 25 to 29 (about 5.0 cases per 1,000 person-years).5PubMed. The health and economic burden of genital warts in a set of private health plans in the United States
After the mid-20s for women and the late 20s for men, rates generally decline with age. That tracks with what you’d expect: sexual debut commonly occurs in the late teens, HPV exposure ramps up quickly, and most people’s immune systems eventually suppress the virus. By the mid-30s, incidence drops substantially, though it never reaches zero.
Why Rates Differ Between the Sexes
Women tend to be diagnosed with genital warts earlier than men, and at slightly higher rates during peak years. Part of this reflects biology: the mucosal tissue of the vulva and vaginal opening may be more susceptible to HPV infection, and warts in these areas can be more visible during routine gynecological exams that women are more likely to attend in their 20s. Men are less likely to seek routine genital exams at the same age, which can delay diagnosis.
Research on insurance claims has found that the age patterns of new genital wart diagnoses differ by sex in ways that may be shaped by differences in health-seeking behavior and health awareness, not just infection timing.6PubMed. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States In other words, the gap between men’s and women’s reported rates partly reflects the fact that young women are more likely to be in a doctor’s office where the warts get noticed. This is one of the reasons researchers caution against reading the sex difference purely as a biological one.
The HPV Types Behind Genital Warts
More than 90% of genital warts are caused by HPV types 6 and 11, which are classified as low-risk because they very rarely lead to cancer.7PubMed Central. Epidemiology and pathology of HPV disease in males This is worth understanding because it explains both the promise and the limits of vaccination: vaccines that cover types 6 and 11 can prevent the vast majority of genital warts, but the two-dose bivalent vaccine (Cervarix) that only targets the high-risk cancer-causing types 16 and 18 does not protect against warts at all. The quadrivalent and nine-valent vaccines (Gardasil and Gardasil 9) do cover types 6 and 11, which is why countries using those formulations have seen dramatic declines in wart diagnoses.
It is possible for a single person to be infected with multiple HPV types at once. Genotyping studies have found that while types 6 and 11 dominate in wart tissue, high-risk types like 18, 51, and others sometimes show up alongside them.8Biomolecular and Health Science Journal. Distribution Genotype High Risk (HR) And Low Risk (LR) Human Papillomavirus (HPV) at Condyloma Acuminata That co-infection is clinically relevant because the visible warts themselves are benign, but the presence of genital warts can serve as a marker for additional HPV exposure, including to cancer-causing types.
Groups with Higher Rates
Two populations stand out for having genital wart rates well above the general average: men who have sex with men and people living with HIV.
Among men who have sex with men attending sexual health clinics in Australia, about 4% presented with anal warts and about 1.6% with penile warts, giving an anal-to-penile ratio of roughly 2.6 to 1.9PubMed Central. Ratio of anogenital warts between different anatomical sites in homosexual and heterosexual individuals in Australia, 2002–2013 The distribution reflects the anatomy of sexual contact. Anal HPV infection was found in about 90% of men who have sex with men who had external genital warts, compared with about 39% of heterosexual men with the same condition.10PubMed. High Prevalence of Human Papillomavirus on Anal and Oral Samples from Men and Women with External Anogenital Warts That same study found that genital warts act as a clinical marker for broader HPV infection, including high-risk types at anal and oral sites. For women with genital warts, anal high-risk HPV was also common, at about 59%.
HIV substantially worsens the picture. In one study, roughly 31% of HIV-positive men had anogenital warts.11The Open AIDS Journal. Prevalence of Anogenital Warts in Men with HIV/AIDS and Associated Factors Beyond prevalence, HIV makes treatment far less durable. After successful wart removal, relapses within a year occurred in about 66% of HIV-positive patients, compared with about 27% of HIV-negative patients. Multiple relapses were even more lopsided: roughly 29% of HIV-positive patients relapsed more than once, versus around 1.3% of HIV-negative controls.12PubMed. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls The immune suppression from HIV makes it much harder for the body to keep HPV in check, which is why warts recur so aggressively.
How Vaccination Has Changed the Numbers
Countries that introduced quadrivalent HPV vaccination early, particularly Australia and several European nations, have seen striking drops in genital wart diagnoses among young people. Australia launched its national female vaccination program in 2007, and within 30 months the proportion of young women diagnosed with genital warts at sexual health clinics had fallen by 59%.13Sexually Transmitted Infections. A National Program with a National impact: quadrivalent HPV vaccination and genital warts in Australia, 2004–2010
Germany, which had lower overall vaccination uptake, still saw meaningful declines. A long-term cohort study following young women found that the lifetime risk of developing genital warts dropped from about 4.7% in an earlier cohort to roughly 1.7% in a later one, and the overall lifetime risk among all women studied fell from 3.1% in 2010 to 1.2% in 2015.14PubMed Central. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany The effect was statistically clear even in a setting where vaccination coverage was modest, which hints at the power of even partial population-level immunity.
A Cochrane review comparing vaccine types found that the quadrivalent vaccine dramatically reduced anogenital warts compared to controls, with rate ratios as low as 0.11, meaning roughly 89% fewer wart cases among vaccinated individuals.15PubMed Central. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
Herd Protection and Unvaccinated Men
One of the more interesting epidemiological effects of female-only HPV vaccination programs was the indirect protection they offered to unvaccinated heterosexual men. In Australia, researchers found that heterosexual men whose female partners were young enough to have been eligible for the national vaccination program had roughly half the odds of penile warts compared to men whose partners were older and unvaccinated.16PubMed. Association between sexual mixing and genital warts in heterosexual men in Australia The logic is straightforward: if a man’s sexual partners are less likely to carry HPV 6 and 11 because they were vaccinated, the man is less likely to get infected and develop warts.
This herd effect did not extend equally to all men. Men who have sex with men did not benefit from female-only vaccination programs in the same way, since their sexual networks involve less overlap with vaccinated women. This was one of the arguments that eventually led many countries, including Australia, to extend HPV vaccination to boys and young men. Gender-neutral vaccination programs close that gap and generate stronger herd protection across all sexual networks.
Genital Warts in Older Adults
While genital warts overwhelmingly affect people in their 20s and 30s, they do not vanish after middle age. HPV can remain latent in the body for years or even decades, and factors that weaken the immune system in older adults, including normal age-related immune decline, chronic illness, or immunosuppressive medication, can allow the virus to reactivate and produce warts long after the initial infection.
Clinical case reports have documented genital warts in patients in their 70s, sometimes following new sexual contacts facilitated by erectile dysfunction medications and shifts in sexual behavior among older populations.17PubMed Central. Anogenital Warts in Geriatrics: Immunosenescence and New Sexual Contacts? A Case Report These cases are uncommon enough to merit individual write-ups in medical journals, but they serve as a reminder that genital warts are not exclusively a young person’s problem. Clinicians who assume a genital lesion in an older patient must be something else can miss the diagnosis.
Transmission Between Partners
HPV is one of the most transmissible sexually transmitted infections, and the types that cause warts are no exception. A study of heterosexual couples estimated the transmission rate of HPV 6 at about 2.5 per 100 person-months, meaning that among couples where one partner carries the virus, there is a meaningful chance of the other partner becoming infected within a few months of regular sexual contact.18PubMed Central. Sex- and type-specific genital human papillomavirus transmission rates between heterosexual partners Condoms reduce transmission but do not eliminate it, because HPV can infect skin in the genital area that is not covered by a condom.
Not everyone who catches HPV 6 or 11 develops visible warts, though. Many infections are subclinical, meaning the virus is present but never produces a visible growth. This complicates both epidemiology and partner communication: a person can transmit the virus without ever knowing they had it, and their partner can be infected without developing warts either. The visible wart cases we track in studies represent the tip of an iceberg of HPV 6/11 infection circulating in the population.
The Psychological Weight of a Diagnosis
The physical harm from genital warts is usually mild. They can itch, bleed during sex, or cause cosmetic distress, but they do not become cancerous. The real burden for many patients is psychological. Studies have consistently found that people diagnosed with genital warts report higher rates of anxiety and depression compared to controls, along with reduced social functioning and general quality of life.19PubMed Central. Evaluation of Psychopathology and Quality of Life in Patients with Anogenital Wart Compared to Control Group
A systematic review covering studies from 2018 to 2025 found that between 55% and 80% of patients with genital warts showed clinically significant anxiety or psychological distress, driven by fear of partner rejection and perceived stigma.20Journal of Skin and Sexually Transmitted Diseases. Impact of genital human papillomavirus warts on sexual function and marital relationships: A systematic review of studies from 2018 to 2025 Research from Sweden found that genital warts were associated with measurably impaired health and quality of life in a clinical sample, on a level comparable to genital herpes.21PubMed Central. How Common Are Genital Warts? Rates by Age and Sex
This matters for understanding the true burden of the disease. If you only look at physical complications, genital warts seem relatively minor. But the shame and anxiety many people experience, especially around sexual relationships, can persist well after the warts themselves have been treated. That psychological toll is one of the underappreciated reasons why prevention through vaccination is considered so valuable.
The Economic Side
Genital warts consume a surprising amount of healthcare resources for a condition that is not life-threatening. In the United States, individual episodes of care averaged about 3.1 physician visits and cost roughly $436 per episode in insurance claims data from the year 2000.5PubMed. The health and economic burden of genital warts in a set of private health plans in the United States Multiply that across hundreds of thousands of cases per year and the aggregate costs become substantial.
Data from the Netherlands illustrates how costs have trended upward even in a country with relatively good access to primary care. Total primary care costs for genital warts there more than doubled between 2011 and 2021, from about €2.3 million to €4.9 million. When referrals to specialists were included, costs reached €5.8 million by 2021. The cost per individual case also climbed, from about €72 to roughly €99 over the same period in primary care alone.22BMJ Open. Epidemiological trends and economic burden of genital warts in Dutch primary care That upward trend reflects not only more diagnoses but also rising treatment and consultation costs. Countries that have seen sharp declines in wart incidence through vaccination are beginning to see a corresponding economic dividend, though the full savings depend on maintaining high vaccine coverage over time.